MAPT and early-onset autosomal dominant Alzheimer disease: Interestingly, tau protein was the target of previously published works on active peptide vaccines for the treatment of Alzheimer disease, targeting either phosphorylated or non-phosphorylated tau protein, which also entered clinical studies [48].